Paclitaxel, carboplatin, and hexamethylmelamine (Taxchex) as first-line therapy for ovarian cancer

Cancer Journal from Scientific American

Volumn 5, Issue 6, 1999, Pages 348-355

  Hartenbach, Ellen M ^a,c   Harris, L S ^a   Bailey, H H ^a   Grosen, E A ^a   Larrison, E ^a   Chen, D ^b   Twiggs, L B ^b   Schink, J C ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c University of Wisconsin Health   (United States)

Author keywords

Altretamine; Carboplatin; Hexamethlymelamine; Ovarian cancer; Paclitaxel; Quality of life

Indexed keywords

ALTRETAMINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; ANTINEOPLASTIC AGENT; PACLITAXEL;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MULTICENTER STUDY; NEUTROPENIA; OVARY CANCER; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; THROMBOCYTOPENIA; MIDDLE AGED; MORTALITY; OVARY TUMOR; PILOT STUDY; PROSPECTIVE STUDY; PSYCHOLOGICAL ASPECT;

ADULT; AGED; ALTRETAMINE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; FEMALE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PACLITAXEL; PILOT PROJECTS; PROSPECTIVE STUDIES; QUALITY OF LIFE;

EID: 0033238030     PISSN: 10814442     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. American Cancer Society. Cancer Facts and Figures - 1997. Atlanta: American Cancer Society, 1997.
2. McGuire WP, Ozols RF. Chemotherapy of advanced ovarian cancer. Semin Oncol 1998;25:340-348.
3. NIH Consensus Development Panel on Ovarian Cancer. Ovarian cancer: screening, treatment, and follow-up. JAMA 1995;273: 491-497.
4. Alberts DS, Green S, Hannigan EVet al. Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer. J Clin Oncol 1992;10:706-717.
5. Swenerton K, Jeffrey J, Stuart G et al. Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: a randomized phase III study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1992;10:718-726.
6. Alberts DS. Carboplatin versus cisplatin in ovarian cancer. Semin Oncol 1995;22:88-90.
7. Advanced Ovarian Cancer Trialists Group. Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. BMJ 1991;303:884-893.
8. Lorigan PC, Crosby T, Coleman RE. Current drug treatment guidelines for epithelial ovarian cancer. Drugs 1996;51:571-584.
9. Alberts DS. Clinical pharmacology of carboplatin. Semin Oncol 1990;17:6-8.
10. Wagstaff AJ, Ward A, Benfield P et al. Carboplatin: a preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the treatment of cancer. Drugs 1989; 37:162-190.
11. Calvert AH, Newell DR, Gumbrell LA et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989;7:1748-1756.
12. Jodrell DI, Egorin MJ, Canetta RM et al. Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. J Clin Oncol 1992;20:520-528.
13. McGuire WP, Rowinsky EK, Rosenshein NB et al. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 1989;111:273-279.
14. Einzig AI, Wiernik PH, Sasloff J et al. Phase II study and long-term follow-up of patients treated with taxol for advanced ovarian adenocarcinoma. J Clin Oncol 1992;10:1748-1753.
15. McGuire WP, Hoskins WJ, Brady MR et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334:1-6.
16. Thigpen T, Vance RB, McGuire WP et al. The role of paclitaxel in the management of coelomic epithelial carcinoma of the ovary: a review with emphasis on the Gynecologic Oncology Group experience. Semin Oncol 1995;22:23-31.
17. Ozols RF. Gynecologic Oncology Group trials in ovarian carcinoma. Semin Oncol 1997;24[1 suppl 2]:S2-10-S2-12.
18. Ozols RF. Future directions in me chemotherapy of ovarian cancer. Semin Oncol 1997;24[5 suppl 15]:S15-86-S15-90.
19. Connelly E, Markman M, Kennedy A et al. Paclitaxel delivered as a 3-hr infusion with cisplatin in patients with gynecologic cancers: unexpected incidence of neurotoxidty. Gynecol Oncol 1996;62: 166-168.
20. Bookman MA, Kloth DD, Kover PE et al. Intravenous prophylaxis for paclitaxel-related hypersensitivity reactions. Semin Oncol 1997;24[6 suppl 19]:S19-13-S19-15.
21. Bookman MA, Kloth DD, Kover PE et al. Short-course intravenous prophylaxis for a paclitaxel-related hypersensitivity. Ann Oncol 1997;8:611-614.
22. Essayan DM, Kagey-Sobotka A, Colarusso PJ et al. Successful parenteral densensitization to paclitaxel. J Allergy Clin Immunol 1996;97:42-46.
23. Peereboom DM, Donehower RC, Eisenhauer EA et al. Successful re-treatment with taxol aftet major hypersensitivity reactions. J Clin Oncol 1993;11:885-890.
24. Bookman MA, McGuire WP III, Kilpatrick D et al. Carboplatin and paclitaxel in ovarian carcinoma: a phase I study of the Gynecologic Oncology Group. J Clin Oncol 1996;14:1895-1902.
25. ten Bokkel Huinink W, Veenhof C, Huizing M et al. Carboplatin and paclitaxel in patients with advanced ovarian cancer: a dose-finding study. Semin Oncol 1997;24[1 suppl 2]:S2-31-S2-33.
26. ten Bokkel Huinink WW, Veenhof CHN, Helmerhorst TJM et al. Carboplatin and paclitaxel in patients with advanced ovarian cancer: a dose finding study [abstract]. Proc ASCO 1995;14:269.
27. Siddiqui N, Bailey N, Memon M et al. A phase I/pharmacokinetic study of escalating paclitaxel in combination with carboplatin dosed at a fixed area under the curve in epithelial ovarian cancer [abstract], Proc ASCO 1995;14:271.
28. Bookman MA, McGuire WP, Kilpatrick D et al. Phase I Gynecologic Oncology Group study of 3-h and 24-h paclitaxel with carboplatin as initial therapy for advanced epithelial ovarian cancer [abstract]. Proc ASCO 1995;14:271.
29. Calvert AH. A review of the pharmacokinetics and pharmacodynamics of combination carboplatin/paclitaxel. Semin Oncol 1997; 24[1 suppl 2]:S2-85-S2-90.
30. Kearns CM, Egorin MJ. Considerations regarding the less-than-expected thrombocytopenia encountered with combination paclitaxel/carboplatin chemotherapy. Semin Oncol 1997;24[2 suppl 2]: S2-91-S2-96.
31. Obasaju CK, Johnson SW, Rogatko A et al. Evaluation of carboplatin pharmacokinetics in the absence and presence of paclitaxel. Clin Cancer Res 1996;2:549-552.
32. van Warmerdam LJC, Huizing MT, Giaccone G et al. Clinical pharmacology of carboplatin administered in combination with paclitaxel. Semin Oncol 1997;24[1 suppl 2]:S2-97-S2-104.
33. Calvert AH, Boddy A, Bailey NP et al. Carboplatin in combination with paclitaxel in advanced ovarian cancer: dose determination and pharmacokinetic and pharamcodynamic interactions. Semin Oncol 1995;22[5 suppl 12]:91-98.
34. Rustin GJS, Nelstrop AE, Crawford M et al. Phase II trial of oral altretamine for relapsed ovarian carcinoma: evaluation of defining response by serum CA125. J Clin Oncol 1997;15:172-176.
35. Schink JC, Harris LS, Greson ES et al. Altretamine an effective salvage chemotherapy after paclitaxel in women with recurrent platinum resistant ovarian cancer [abstract]. Proc ASCO 1995;14:275.
36. Markman M, Blessing JA, Moore D et al. Altretamine (hexamethylmelamine) in platinum-resistant and platinum refractory ovarian cancer: a Gynecologic Oncology Group phase II trial. Gynecol Oncol 1998:69:226-229.
37. Manetta A, Tewari K, Podczaski ES. Hexamethylmelamine as a single second-line agent in ovarian cancer: follow-up report and review of the literature. Gynecol Oncol 1997;66:20-26.
38. Schein PS, Scheffler B, McCulloch W. The role of hexamethylmelamine in the management of ovarian cancer. Cancer Treat Rev 1991;18[suppl A]:67-75.
39. Damia G, D'Incalci M. Clinical pharmacokinetics of altretamine. Clin Pharmacokinet 1995;28:439-448.
40. Ames MM. Hexamethylmelamine: pharmacology and mechanism of action. Cancer Treat Rev 1991;18[suppl A]:3-14.
41. Lee CR, Faulds D. Altretamine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cancer chemotherapy. Drugs 1995;49:932-953.
42. Wharton JT. Hexamethylmelamine (altretamine) activity as a single agent in previously untreated advanced ovarian cancer. Cancer Treat Rev 1991;18[suppl A]:15-21.
43. Edmonson JH, McCormack GW, Fleming TR et al. Comparison of cyclophosphamide plus cisplatin versus hexamethylmelamine, doxorubicin, and cisplatin in combination as initial chemotherapy for stage III and IV ovarian carcinoma. Cancer Treat Rep 1985; 69:1243-1248.
44. Sturgeon JFG, Fine S, Gospodarowicz MK et al. A randomized trial of melphalan alone versus combination chemotherapy in advanced ovarian cancer. Proc ASCO 1982;1:108.
45. Hainsworth JD, Jones HW III, Burnett LS et al. The role of hexamethylmelamine in the combination chemotherapy of advanced ovarian cancer: a comparison of hexamethylmelamine, cyclophosphamide, doxorubicin, and cisplatin (H-CAP) versus cyclophosphamide, doxorubicin, and cisplatin (CAP). Am J Clin Oncol 1990;13:410-415.
46. Bruckner HW, Cohen C, Mandeli J et al. Hexamethylmelamine for the treatment of ovarian cancer: the Mt. Sinai experience. Cancer Treat Rev 1991;18[suppl A]:57-65.
47. Kristensen GB, Baekelandt M, Vergote IB et al. A phase II study of carboplatin and hexamethylmelamine as induction chemotherapy in advanced epithelial ovarian carcinoma. Eur J Cancer 1995; 31A:1778-1780.
48. Frasci G, Comella G, Comella P et al. Carboplatin (CBDCA)-hexamethylmelamine (HMM)-oral etoposide (VP-16) first-line treatment of ovarian cancer patients with bulky disease: a phase II study. Gynecol Oncol 1995;58:68-73.
49. Cella DF, Tulsky DS, Gray G et al. The functional assessment of cancer therapy scale: development and validation of the general measure. J Clin Oncol 1993;11:570-579.
50. Jelliffe RW. Creatinine clearance: bedside estimate. Ann Intern Med 1973;79:604-605.
51. Du Bois A, Vach W, Thomssen C et al. Comparison of the emetogenic potential between cisplatin and carboplatin in combination with alkylating agents. Acta Oncol 1994;33:531-535.
52. Kosmidis P. Quality of life as a new end point. Chest 1996;109: 110S-112S.
53. Moinpour CM, Feigl P, Metch B et al. Quality of life end points in cancer clinical trials: review and recommendations. J Natl Cancer Inst 1989;81:485-495.
54. Nayfield SG, Ganz PA, Moinpour CM et al. Report from a National Cancer Institute workshop on quality of life assessment in cancer clinical trials. Qual Life Res 1992;1:203-210.
55. Kiebert GM, Kaasa S. Quality of life in clinical cancer trials: experience and perspective of the European Organization for Research and Treatment of Cancer. J Natl Cancer Inst Monogr 1996;20: 91-95.
56. Kornblith AB, Thaler HT, Wong G et al. Quality of life of women with ovarian cancer. Gynecol Oncol 1995;59:231-242.
57. Gotay CC. Trial-related quality of life: using quality-of-life assessment to distinguish among cancer therapies. J Natl Cancer Inst Monogr 1996;20:1-6.
58. Ferrell BR, Dow KH, Leigh S et al. Quality of life in long-term cancer survivors. Oncol Nursing Forum 1995;22:915-922.